Oncology

What does team-based cancer care done right look like? Here are two real-word models worth emulating.

A combination melanoma treatment that was just approved by FDA is available through select specialty pharmacies.

A new study investigates whether PET scans can help guide treatment in patients with aggressive non-Hodgkin lymphomas.

A lymphoma expert from the Allegheny Health Network Cancer Institute reveals the status of current and pipeline lymphoma treatments and the three new treatments healthcare executives need to keep on their radar.

New Cardinal Health Specialty Solutions research shares inside information about oncologists’ views about targeted therapies.

The manufacturer of bevacizumab (Avastin), snagged FDA approval for yet another type of cancer.

FDA approved the first biosimilar to Neulasta, as well as a new combination treatment for osteoarthritis pain and hypertension and a new drug to treat chronic lymphocytic leukemia.

The manufacturer of two cancer drugs hiked the price on the medicines despite President Donald Trump’s new plan to lower drug prices.

A study evaluated how treating military veterans with HCV early impacted their risk for non-Hodgkin lymphoma and various other diseases.

Treating patients with cancer is often challenging yet rewarding work. But caring for patients in an urban setting, where some patients don’t speak English and other patients aren’t fully insured and possibly facing significant financial challenges.

Can you identify the latest developments related to the treatment of blood cancers? Test your knowledge.

Here’s how community oncologists seize opportunities to improve the quality of care and create performance metrics.

Montefiore Medical Center in Bronx, New York, is participating in CMS’ oncology care model, a value-based payment arrangement. Find out what new group of staff members is helping it succeed.

Analysis from Avalere shows why healthcare execs should understand how oncology practices are evolving in response to the OCM.

The Center for Blood and Cancer Disorders in Fort Worth, Texas, is participating in many value-based contracts. Here’s how it is successful.

Ron Barkley, president of the Cancer Center Business Development Group, which consults with oncology providers on value-based care arrangements, shares tips.

CEO of a Pennsylvania-based oncology group shares how participating in a new value-based model is changing the care approach.

Healthcare systems stand to lose $6 million if burned out physicians choose to resign or work elsewhere. Here are some ways to curb burnout and its associated costs.

Genetic testing is playing a growing role in diagnosing and treating diseases, particularly when it comes to certain cancers and rheumatic conditions.

Successful CAR T-cell therapy reimbursement begins with careful payer-provider collaboration and taking these two approaches.

Shift represents growing understanding of value of genetic testing for cancers. Find out who is receiving the test and why.

Two new studies reveal that cost-restraints can keep patients from accessing life-preserving cancer drugs.

The impact of VBRs on outcomes, VBRs versus other healthcare reimbursement initiatives, and VBR successes and failures. Pfizer’s Robert Popovian, PharmD, weighs in.

FDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).

Early detection of breast cancer continues to be the best way to save lives and decrease healthcare costs over time, and new technology could help.

Experts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.

Key takeaways for healthcare executives from Bruno Medeiros, MD, associate professor of medicine (hematology) at the Stanford University Medical Center and director of Cancer Center Infusion Area Treatment Services at Stanford Cancer Center.

Acute myeloid leukemia experts share promising new developments on the oncology horizon.

Physicians need to be able to move quickly to care for patients with AML, and they need to have payers on board.